JACC
HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
 QUICK SEARCH:   [advanced]


     


J Am Coll Cardiol, 2002; 39:1924-1929
© 2002 by the American College of Cardiology Foundation
This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ronner, E.
Right arrow Articles by Simoons, M. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ronner, E.
Right arrow Articles by Simoons, M. L.

Early angioplasty in acute coronary syndromes without persistent st-segment elevation improves outcome but increases the need for six-month repeat revascularization

An analysis of the pursuit trial

Eelko Ronner, MD, PhD*{dagger}, Eric Boersma, PhD*, Gert-Jan Laarman, MD, PhD{dagger}, G. Aernout Somsen, MD, PhD{ddagger}, Robert A. Harrington, MD, PhD§, Jaap W. Deckers, MD, PhD*, Eric J. Topol, MD, PhD||, Robert M. Califf, MD, PhD§ and Maarten L. Simoons, MD, PhD*,*

* University Hospital Rotterdam, Rotterdam, The Netherlands
{dagger} Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands
{ddagger} Academic Medical Center, Amsterdam, The Netherlands
§ Duke Clinical Research Institute, Durham, North Carolina, USA
|| Cleveland Clinic Foundation, Cleveland, Ohio, USA



View larger version (19K):

[in a new window]
 
Figure 1 Death and myocardial infarction at 30 days, according to the time of percutaneous coronary intervention (PCI).

 


View larger version (12K):

[in a new window]
 
Figure 2 Occurrence (%) of cardiac complications in patients undergoing percutaneous coronary intervention from day 0 to 30, randomly assigned to glycoprotein IIb/IIIa inhibition (open bars) or placebo (solid bars) for 72 h. MI = myocardial infarction.

 





HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
Copyright © 2002 by the American College of Cardiology Foundation.